CY1111159T1 - Πυκνα διαλυματα μεθοτρεξατης - Google Patents
Πυκνα διαλυματα μεθοτρεξατηςInfo
- Publication number
- CY1111159T1 CY1111159T1 CY20111100118T CY111100118T CY1111159T1 CY 1111159 T1 CY1111159 T1 CY 1111159T1 CY 20111100118 T CY20111100118 T CY 20111100118T CY 111100118 T CY111100118 T CY 111100118T CY 1111159 T1 CY1111159 T1 CY 1111159T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methotrexate
- well
- syringe
- solutions
- cartridge
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Περιγράφονται πυκνά διαλύματα μεθοτρεξάτης, τα οποία είναι κατάλληλα για χρήση δραστικής ουσίας στην παραγωγή παρεντερικώς χορηγούμενου φαρμάκου για την αγωγή φλεγμονωδών αυτοάνοσων παθήσεων. Η μεθοτρεξάτη χρησιμοποιείται σε συγκέντρωση άνω των 25 mg/ml εντός φαρμακευτικά συμβατού διαλύτη. Η εφεύρεση αναφέρεται και σε έτοιμη σύριγγα καθώς και σε φύσιγγα, οι οποίες περιέχουν τέτοιο φαρμακευτικό σκεύασμα-διάλυμα, καθώς και σε εγχυτήρα τύπου στυλό που περιλαμβάνει τέτοια φύσιγγα και/ή έτοιμη σύριγγα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006033837A DE102006033837A1 (de) | 2006-07-21 | 2006-07-21 | Konzentrierte Methotrexat-Lösungen |
EP07786239A EP2046332B1 (de) | 2006-07-21 | 2007-07-20 | Konzentrierte methotrexat-lösungen |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111159T1 true CY1111159T1 (el) | 2015-06-11 |
Family
ID=38640096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100118T CY1111159T1 (el) | 2006-07-21 | 2011-02-03 | Πυκνα διαλυματα μεθοτρεξατης |
Country Status (22)
Country | Link |
---|---|
US (7) | US8664231B2 (el) |
EP (2) | EP2046332B1 (el) |
JP (1) | JP5683810B2 (el) |
KR (1) | KR101260554B1 (el) |
AT (2) | ATE491455T1 (el) |
AU (1) | AU2007276387B2 (el) |
BR (1) | BRPI0715433A2 (el) |
CA (2) | CA2659662C (el) |
CY (1) | CY1111159T1 (el) |
DE (3) | DE102006033837A1 (el) |
DK (1) | DK2046332T3 (el) |
ES (1) | ES2355399T3 (el) |
HR (1) | HRP20110148T1 (el) |
ME (1) | ME01940B (el) |
MX (1) | MX2009000812A (el) |
PL (1) | PL2046332T3 (el) |
PT (1) | PT2046332E (el) |
RS (1) | RS51688B (el) |
RU (1) | RU2403044C1 (el) |
SI (1) | SI2046332T1 (el) |
UA (1) | UA95488C2 (el) |
WO (1) | WO2008009476A2 (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2314182T3 (es) | 2002-02-11 | 2009-03-16 | Antares Pharma, Inc. | Inyector intradermico. |
EP1850892B2 (en) | 2005-01-24 | 2023-04-19 | Antares Pharma, Inc. | Prefilled needle assisted syringe jet injector |
WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
DE102006033837A1 (de) | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
EP2402013A1 (en) * | 2006-11-21 | 2012-01-04 | Kalobios Pharmaceuticals, Inc. | Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist |
WO2009114542A1 (en) | 2008-03-10 | 2009-09-17 | Antares Pharma, Inc. | Injector safety device |
EP2318075B1 (en) | 2008-08-05 | 2019-05-22 | Antares Pharma, Inc. | Multiple dosage injector |
EP2408493A1 (en) | 2009-03-20 | 2012-01-25 | Antares Pharma, Inc. | Hazardous agent injection system |
US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
PT2822618T (pt) | 2012-03-06 | 2024-03-04 | Antares Pharma Inc | Seringa pré-cheia com característica de força de rutura |
JP6457383B2 (ja) | 2012-04-06 | 2019-01-23 | アンタレス・ファーマ・インコーポレーテッド | テストステロン組成物の針支援式ジェット注入投与 |
WO2013169804A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
CN110404140B (zh) | 2013-01-29 | 2022-09-30 | 赛诺菲-安万特德国有限公司 | 电子模块和药物输送装置 |
ES2763633T3 (es) | 2013-02-11 | 2020-05-29 | Antares Pharma Inc | Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida |
ES2742046T3 (es) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Inyector de dosis con sistema de piñón |
WO2014165136A1 (en) * | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
JPWO2015147018A1 (ja) * | 2014-03-28 | 2017-04-13 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤 |
WO2015161015A1 (en) * | 2014-04-16 | 2015-10-22 | Antares Pharma, Inc. | Method of achieving increased systemic availability of methotrexate |
WO2015183213A1 (en) | 2014-05-28 | 2015-12-03 | Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid |
JP2017066073A (ja) * | 2015-09-29 | 2017-04-06 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤およびその保存方法 |
KR102095284B1 (ko) | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
GB2591681A (en) * | 2018-08-29 | 2021-08-04 | Ftf Pharma Private Ltd | Methotrexate pharmaceutical composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4357971A (en) * | 1980-09-19 | 1982-11-09 | Cyberon Corporation | Syringe gauging, loading and injection apparatus |
US5279586A (en) * | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Reusable medication delivery pen |
JPH08505543A (ja) * | 1992-11-19 | 1996-06-18 | テブロ ソシエテ アノニム | 予充填注射器用の使い捨て自動注射装置 |
US5593671A (en) | 1994-07-01 | 1997-01-14 | American Cyanamid Company | Method of attenuating lung capillary leak in a mammal |
US5542934A (en) * | 1995-06-02 | 1996-08-06 | Silver; Richard M. | Multiple carpule hypodermic syringe |
US6544504B1 (en) | 1999-07-28 | 2003-04-08 | Schering Corporation | Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy |
MXPA03007878A (es) * | 2001-03-02 | 2004-07-08 | Medimmune Inc | Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina. |
US20040176381A1 (en) * | 2003-03-06 | 2004-09-09 | Walsh Michael J. | Methotrexate compliance packaging |
US20050153969A1 (en) * | 2004-01-13 | 2005-07-14 | Iomed, Inc. | Methods for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicament |
DE102006033837A1 (de) * | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
-
2006
- 2006-07-21 DE DE102006033837A patent/DE102006033837A1/de active Pending
-
2007
- 2007-07-20 RU RU2009106053/15A patent/RU2403044C1/ru active
- 2007-07-20 DE DE202007019703.9U patent/DE202007019703U1/de not_active Expired - Lifetime
- 2007-07-20 UA UAA200901346A patent/UA95488C2/ru unknown
- 2007-07-20 PT PT07786239T patent/PT2046332E/pt unknown
- 2007-07-20 AT AT07786239T patent/ATE491455T1/de active
- 2007-07-20 AU AU2007276387A patent/AU2007276387B2/en active Active
- 2007-07-20 EP EP07786239A patent/EP2046332B1/de active Active
- 2007-07-20 AT ATGM50122/2015U patent/AT14872U1/de not_active IP Right Cessation
- 2007-07-20 KR KR1020097003655A patent/KR101260554B1/ko active IP Right Grant
- 2007-07-20 PL PL07786239T patent/PL2046332T3/pl unknown
- 2007-07-20 RS RS20110010A patent/RS51688B/en unknown
- 2007-07-20 ES ES07786239T patent/ES2355399T3/es active Active
- 2007-07-20 DK DK07786239.9T patent/DK2046332T3/da active
- 2007-07-20 CA CA2659662A patent/CA2659662C/en active Active
- 2007-07-20 CA CA2869671A patent/CA2869671A1/en not_active Abandoned
- 2007-07-20 MX MX2009000812A patent/MX2009000812A/es active IP Right Grant
- 2007-07-20 US US12/374,528 patent/US8664231B2/en active Active
- 2007-07-20 SI SI200730475T patent/SI2046332T1/sl unknown
- 2007-07-20 WO PCT/EP2007/006491 patent/WO2008009476A2/de active Application Filing
- 2007-07-20 JP JP2009521153A patent/JP5683810B2/ja active Active
- 2007-07-20 EP EP10194145A patent/EP2292235A3/de not_active Withdrawn
- 2007-07-20 DE DE502007005972T patent/DE502007005972D1/de active Active
- 2007-07-20 ME MEP-2011-207A patent/ME01940B/me unknown
- 2007-07-20 BR BRPI0715433-0A patent/BRPI0715433A2/pt not_active Application Discontinuation
-
2011
- 2011-02-03 CY CY20111100118T patent/CY1111159T1/el unknown
- 2011-02-28 HR HR20110148T patent/HRP20110148T1/hr unknown
-
2014
- 2014-02-07 US US14/175,357 patent/US20140155405A1/en not_active Abandoned
- 2014-03-03 US US14/195,117 patent/US20140179703A1/en not_active Abandoned
-
2015
- 2015-03-02 US US14/635,542 patent/US20150164902A1/en not_active Abandoned
-
2017
- 2017-05-11 US US15/592,882 patent/US20170246172A1/en not_active Abandoned
-
2018
- 2018-10-05 US US16/152,463 patent/US10610531B2/en active Active
-
2020
- 2020-02-25 US US16/800,584 patent/US11944629B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
ATE471144T1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
EA201171376A1 (ru) | Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса | |
ECSP045140A (es) | Formulaciones farmacéuticas derivadas del platino | |
EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
EA200401317A1 (ru) | Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
CY1106430T1 (el) | Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο | |
MX2022008130A (es) | Derivado de insulina. | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
EA200870183A1 (ru) | Долговременное лечение вич-инфекции | |
EA200501105A1 (ru) | Фармацевтическая композиция | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
CY1116161T1 (el) | Kit για παρεντερικη χορηγηση φαρμακων | |
EA200701615A1 (ru) | Новые лекарственные средства для лечения заболеваний дыхательных путей | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат |